Żorniak Michał, Beyer Georg, Mayerle Julia
Department of Gastroenterology, Medical University of Silesia, Katowice, Poland.
Department of Medicine II, University Hospital, LMU Munich, Munich, Germany.
Visc Med. 2019 Apr;35(2):82-89. doi: 10.1159/000497290. Epub 2019 Mar 25.
Acute pancreatitis (AP) is a potentially life-threatening common gastrointestinal disorder with increasing incidence around the globe. Although the majority of cases will take an uneventful, mild course, a fraction of patients is at risk of moderately severe or severe pancreatitis which is burdened with substantial morbidity and mortality. Early identification of patients at risk of a severe disease course and an adopted treatment strategy are crucial to avoid adverse outcomes.
In this review we summarize the most recent concepts of severity grading in patients diagnosed with AP by adopting recommendations of current guidelines and discussing them in the context of the available literature. The severity of AP depends on the presence of local and/or systemic complications and organ failure. To predict the severity early in the disease course, host-specific factors (age, comorbidities, body mass index), clinical risk factors (biochemical and physiological parameters and scoring systems), as well as the response to initial therapy need to be considered and revisited in the short term. Depending on the individual risk and comorbidity the initial treatment can be guided, which will be discussed in the second part of this review.
Predicting the severity of AP and adapting the individual treatment strategy requires multidimensional risk assessment and close observation during the early phase of AP development.
急性胰腺炎(AP)是一种潜在危及生命的常见胃肠道疾病,全球发病率呈上升趋势。尽管大多数病例病情平稳、病程较轻,但部分患者有发生中度或重度胰腺炎的风险,这类患者的发病率和死亡率都很高。早期识别有重症病程风险的患者并采取相应的治疗策略对于避免不良后果至关重要。
在本综述中,我们采用当前指南的建议并结合现有文献进行讨论,总结了诊断为AP的患者严重程度分级的最新概念。AP的严重程度取决于局部和/或全身并发症以及器官衰竭的存在情况。为了在疾病早期预测严重程度,需要考虑宿主特异性因素(年龄、合并症、体重指数)、临床危险因素(生化和生理参数以及评分系统)以及对初始治疗的反应,并在短期内进行重新评估。根据个体风险和合并症情况,可以指导初始治疗,这将在本综述的第二部分进行讨论。
预测AP的严重程度并调整个体化治疗策略需要在AP发展的早期阶段进行多维度风险评估和密切观察。